Since acquiring EpiPen® Auto-Injector in 2007, we have worked diligently and invested significantly to enhance EpiPen® Auto-Injector and make it more available.
- The EpiPen® Auto-Injector in the market today is substantially different than the one we acquired. We launched a next-generation device in 2009 which represented a complex and innovative re-design. The sterile injectable drug-in-device has more than 15 critical component parts and delivers the epinephrine drug within seconds.
- We continue to invest in product improvements, such as a formulation with a longer shelf life that would extend the period between refills.
- Forty-eight states now permit epinephrine auto injectors in schools without a prescription for a specific child. And we have donated more than 700,000 EpiPen Auto-Injectors to more than 66,000 participating schools (more than half of all public schools), with no strings attached.
- More broadly, the total population of people having access to EpiPen® Auto-Injector has increased by 80% in the last few years. Approximately 85% of consumers who are prescribed an EpiPen® Auto-Injector pay less than $100 for a 2 unit package, and a majority pay less than $50.
We are diligently working to provide the generic as soon as possible. Before Mylan can offer the generic a number of action items must be addressed including (1) assuring that sufficient inventory will be available to meet anticipated orders, (2) creating the necessary packaging for the product, and (3) creating the necessary labelling for the product. Once the relevant product materials have been created, operational use must be appropriately evaluated and sufficient quantities will then be manufactured to fulfill anticipated orders.
The generic to EpiPen® Auto-Injector will be offered at a list price of $300 per two-pack carton, which represents a discount of more than 50% to the list price of the branded medicine.
Given the distribution channel that will be utilized, Mylan will be able to offer a generic version at a price that is half of the branded version. We anticipate that 85% of prescriptions will shift to the generic product, saving customers more than $1 billion.
We have set-up a media room with company statements, as well as several resources about our new patient access programs, here.